Antigens, CD28

• 

  Subject Areas on Research

  • A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection. 
  • Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. 
  • An expanded role of the tumor suppressor TSC1 in T cell tolerance. 
  • Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. 
  • Biologics in organ transplantation. 
  • CD28 costimulatory signal induces protein arginine methylation in T cells. 
  • CD28 is required for germinal center formation. 
  • CD28 ligation induces rapid tyrosine phosphorylation of the linker molecule LAT in the absence of Syk and ZAP-70 tyrosine phosphorylation. 
  • CD28 ligation induces tyrosine phosphorylation of Pyk2 but not Fak in Jurkat T cells. 
  • CD28 negative T cells: is their loss our gain? 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. 
  • CD7 and CD28 are required for murine CD4+CD25+ regulatory T cell homeostasis and prevention of thyroiditis. 
  • CTLA-4-Mediated inhibition of early events of T cell proliferation. 
  • CTLA4Ig: bridging the basic immunology with clinical application. 
  • CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. 
  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. 
  • Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells. 
  • Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. 
  • Costimulation blockade: towards clinical application. 
  • Cutting edge: in vivo identification of TCR redistribution and polarized IL-2 production by naive CD4 T cells. 
  • Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. 
  • Electron transport complex I is required for CD8+ T cell function. 
  • Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium. 
  • FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 
  • Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. 
  • IFN-α inhibits telomerase in human CD8⁺ T cells by both hTERT downregulation and induction of p38 MAPK signaling. 
  • Immunologic characterization of CD7-deficient mice. 
  • Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. 
  • Involvement of linker for activation of T cells in the costimulatory signaling pathways. 
  • In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia. 
  • K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. 
  • Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. 
  • Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. 
  • Notch 1 signaling regulates peripheral T cell activation. 
  • PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. 
  • Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. 
  • Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. 
  • Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. 
  • Premature cell senescence and T cell receptor-independent activation of CD8+ T cells in juvenile idiopathic arthritis. 
  • Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. 
  • Regulation of T cell receptor- and CD28-induced tyrosine phosphorylation of the focal adhesion tyrosine kinases Pyk2 and Fak by protein kinase C. A role for protein tyrosine phosphatases. 
  • Secondary lymphoid tissue and costimulation-blockade resistant rejection: A nonhuman primate renal transplant study. 
  • Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. 
  • T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis. 
  • T cell activation up-regulates the expression of the focal adhesion kinase Pyk2: opposing roles for the activation of protein kinase C and the increase in intracellular Ca2+. 
  • T cell-mediated elimination of B7.2 transgenic B cells. 
  • The CD28 signaling pathway regulates glucose metabolism. 
  • The calm after the cytokine storm: lessons from the TGN1412 trial. 
  • Tolerance: is it achievable in pediatric solid organ transplantation? 
  • Tumor suppressor TSC1 is critical for T-cell anergy. 
  • Viral-induced CD28 loss evokes costimulation independent alloimmunity. 
• 

  Keywords of People

  • Zhong, Xiaoping, Professor of Pediatrics, Immunology